Back to results
US 6,585,995 B1Granted
Methods and compositions for treating platelet-related disorders
OwnerStephen R. Hansoninventor
Life of this patent
Estimating the term…
Abstract
The invention relates to the prophylactic and therapeutic treatment of subjects for the purpose of inhibiting vaso-occlusive events, including embolism, by administering agents which reduce the number of circulating platelets to below normal levels. Methods and pharmaceutical preparations comprising such agents are provided.
Claims96
A method for treating a subject to inhibit a vaso-occlusive event comprising
- administering to a subject in need of such treatment an agent that reduces platelet count in the subject in an amount effective to reduce platelet count in the subject to at least a low normal level, wherein the subject does not have a hematological proliferative disorder,
- wherein the agent is not an MPL pathway inhibitory agent.
A method for treating a subject to inhibit a vaso-occlusive event comprising
- administering to a subject in need of such treatment an agent that reduces platelet counts in the subject in an amount effective to reduce platelet count in the subject to at least a low normal level,
- wherein the agent is administered for at least thirty days, and wherein the agent is not an MPL pathway inhibitory agent.
A method for treating a subject to inhibit a vaso-occlusive event comprising
- administering to a subject in need of such treatment an agent that reduces platelet count in the subject in an amount effective to reduce platelet count in the subject to at least a low normal level, wherein the subject does not have a hematological proliferative disorder, and
- wherein the agent is anagrelide or a derivative thereof.
A method for treating a subject to inhibit a vaso-occlusive event comprising
- administering to a subject in need of such treatment an agent that reduces platelet counts in the subject in an amount effective to reduce platelet count in the subject to at least a low normal level,
- wherein the agent is administered for at least thirty days;
- and wherein the agent is anagrelide or a derivative thereof.
Dependencies are inferred from the claim text.